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Abstract: (1) Background. The main goal of this work was to develop a fluorescent dye-labelling 
technique for our previously described nanosized platform, citrate-coated Prussian blue (PB) 
nanoparticles (PBNPs). In addition, characteristics and stability of the PB nanoparticles labelled with 
fluorescent dyes were determined. (2) Methods. We adsorbed the fluorescent dyes Eosin Y and 
Rhodamine B and methylene blue (MB) to PB-nanoparticle systems. The physicochemical properties 
of these fluorescent dye-labeled PBNPs (iron(II);iron(III);octadecacyanide) were determined using 
atomic force microscopy, dynamic light scattering, zeta potential measurements, scanning- and 
transmission electron microscopy, X-ray diffraction, and Fourier-transformation infrared 
spectroscopy. A methylene-blue (MB) labelled, polyethylene-glycol stabilized PBNP platform was 
selected for further assessment of in vivo distribution and fluorescent imaging after intravenous 
administration in mice. (3) Results. The MB-labelled particles emitted a strong fluorescent signal at 
662 nm. We found that the fluorescent light emission and steric stabilization made this PBNP-MB 
particle platform applicable for in vivo optical imaging. (4) Conclusion. We successfully produced 
a fluorescent and stable, Prussian blue-based nanosystem. The particles can be used as a platform 
for imaging contrast enhancement. In vivo stability and biodistribution studies revealed new 
aspects of the use of PBNPs. 
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1. Introduction 
Optical methods are simple and easy ways of imaging in biomedical research. They offer 
opportunities from simple observation of subjects to advanced methods for the imaging of tumors 
and different metabolic pathways using different kinds of spectroscopy and microscopy [1]. The 
major drawback of this method lies in the properties of light: tissue absorption and scatter strongly 
depend on the wavelength of light as well as the tissues themselves. Strong autofluorescence of the 
highly perfused tissues, e.g., muscles, skin, and hair scatter limit the tissue penetration and contrast 
of optical methods. Fluorophores, emitting light at higher wavelengths can potentially result in a 
better signal-to-noise ratio and a better image [2–4]. On the other hand, fluorophores alone are not 
able to mark specific tissues; their premature metabolism after intravenous administration often leads 
to decreased uptake in the target tissue or tumor. Yet, their toxicity to the healthy tissues is another 
issue. To overcome these drawbacks, chemical or physicochemical solutions would connect these 
NIR fluorophores to other structures, e.g., nanoparticles or proteins, which could solve the toxicity 
and sensitivity issues, allowing the microdosing of these agents [4,5]. 
Mesoporous nanoparticles have been reported, capable of fluorescent optical imaging [6–9]. The 
mesoporous structure itself could lend the particle absorbing properties of ions, anticancer drug, or 
even fluorescent dyes to the corresponding particles [6–10]. However, the synthesis of such particles 
can range from a very wide range of chemical synthesis techniques from the polycondensation 
process to thermal oxidation to thermal condensation; the basics of nanoparticle separation via 
centrifugation, rinsing the samples using ethanol to remove “unwanted,” unreacted contaminants 
along with dialyzing the samples could be easily translated and implemented into any synthesis 
process [6,9]. 
Methylene blue, with its excitation wavelength at 633 nm and emission at 662 nm could be a 
potential candidate for fluorescent imaging. Its emission wavelength is in the diagnostic window 
(650–900 nm), where the extinction coefficients of oxyhemoglobin, deoxyhemoglobin, and water are 
the lowest [4]. Furthermore, methylene blue is on the World Health Organization List of Essential 
Medicines, the safest and most effective medicines needed in a health system and has been used 
widely in clinical and basic research [10,11]. Its properties and widespread global use make it a 
promising candidate for the fluorescent labelling of a multimodal imaging system, a Prussian blue 
nanoparticle-based nanoteragnostic agent (Prussian blue (PB) nanoparticles (PBNPs)). 
Previous studies prove that PBNPs could possibly act as zeolitic and porous structures, absorbing 
metallic cations and gases in their pores, although the exact binding mechanisms were not fully 
described and published [12–14]. It was also previously reported that PBNPs could have a great 
potential as multimodal contrast agents as well as potential drugs for photodynamic therapy 
[7,13,15,16]. Equipped with a suitable biocompatible citrate layer would help to stabilize the particles 
and render them capable to form surface dendrimers when polyethylene glycols are added to the PBNP 
solution [7,12]. Just like with PEGylation, these surface dendrimers would prevent the aggregation of 
the nanosystem and provide long-term stability in physiological conditions [17,18]. 
Our main goal was to create a fluorescently labeled Prussian blue nanoparticle (PBNP) 
(iron(II);iron(III);octadecacyanide)-based nanosystem for preclinical fluorescent imaging. The crucial 
quality of the platform should be as follows: first, it should be a stable nanosystem, which does not 
aggregate over long periods of time; second, the emission of a fluorescent signal that could be 
detected in living organisms to make the particle suitable for in vivo imaging; and third, a clearance 
mechanism to reduce possible side effects but also to slow down accumulation in the monocyte-
macrophage system, the liver and spleen. We wished to also take advantage of the biocompatible 
coating of the particle, thus connecting the potential fluorescent dyes and stabilizers to PBNPs. To 
this end, we selected and tested the fluorescent dyes eosin Y, rhodamine B, and methylene blue for 
further sorption to the PB nanoparticles, both with and without further (or preceding) PEGylation. 
We selected a 3-h imaging time point evaluation in order to model a clinically also relevant situation 
as in the case of currently running image-guided surgery clinical studies of fluorescent contrast 
materials. 
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2. Materials and Methods 
2.1. Synthesis of PBNPs 
Citrate-coated PBNPs were synthesized by following the method published by Shokouhimehr 
and colleagues with some modifications. [14]. Briefly, PBNPs were prepared by slowly adding 20 mL 
of 1.0 mM Fe(III) chloride anhydrous (FeCl3; Sigma-Aldrich, Hunary) solution with 0.5 mmol of citric 
acid (Sigma-Aldrich) to a solution containing an equimolar amount of potassium ferrocyanide 
anhydrous (K4[Fe(CN)6]; Sigma-Aldrich, Hungary) under vigorous stirring for 15 min at 40 °C. The 
products were isolated with centrifugation at 21,130 rcf (Eppendorf 5424R centrifuge) at 4 °C. 
2.2. Fluorescent Labelling 
Eosin Y and rhodamine B were adsorbed to the particles as reported in Supplementary 
Information (Table S1). For fluorescent labelling, the concentrated methylene blue (MB; Sigma-
Aldrich) stock solution was diluted twofold and filtered through a 0.22 µm membrane filter (MILLEX 
GP 0.22 µm; Merck Millipore Ltd.). Further, 200 µL of this filtered solution was added to 2 mL of the 
PBNP solution. This would result in absorbed MB on the mesoporous surface of the biocompatible 
PBNPs. After that, two main approaches were made: 
a. The synthesized PBNPs were labelled after centrifugation of “bare” PBNPs at 4 °C, using 21,130 
rcf. Thereafter, the PEGylation process was performed and the solution was dialyzed against 
phosphate buffer saline solution (pH = 6.8; Ph.Eur. 8.). 
b. The PBNP-MB mixture was centrifuged at 21,130 rcf (Eppendorf 5424R centrifuge) at 4 °C. Then, 
the PBNP-MBs were PEGylated, dialyzed, and stored at 2–8 °C until further use. 
2.3. PEGylation of PBNPs 
For the PEGylation, PEG 3000 (for molecular biology; Sigma Aldrich Germany) was available in 
monodisperse solution, while PEG 6000 (for synthesis) and PEG 8000 (for synthesisUSP) (Sigma 
Aldrich, Hungary) were commercially sold in solid form. At first, these power-based agents were 
dissolved in 50% ethanol–water mixture the final PEG content was set to 10 w/w%. 
PBNP-MB solutions (2 mg/mL) were prepared by adding distilled water (Milli-Q) to the stock 
MB-labelled PBNP solution. After 15 min incubation time at room temperature, different PEG 
solutions (PEG 3000, PEG 6000, and PEG 8000) were added to the PBNP-MB solutions and dialyzed 
for 24 h (14 kDa filter) (Sigma-Aldrich, Hungary) in phosphate buffer saline solution (pH = 6.8; 
Ph.Eur. 8.). Different v/v% concentration compositions (PEG 3000: 1.47-1.96-2.44-3.85-9.09, PEG 6000: 
1.47-1.96-2.44-3.85, and PEG 8000: 1.47-1.96-2.44) were prepared and characterized in the following 
with DLS and Zetasizer instruments. Other details are available in the Supplemental Information. 
2.4. DLS and Zeta Measurements 
The absorbance of the samples was measured at 633 nm with a Model 8453 UV–VIS 
spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). The surface charge and 
hydrodynamic diameter of the particles were determined using a Zetasizer Nano ZS (Malvern 
Instruments Ltd., Worcestershire, UK). DLS measurement was performed at 37 °C in backscattering 
mode (detector fixed at 173°) using a 633 nm He-Ne laser. Samples were measured in a reusable 
quartz cuvette (type PCS1115 6G; Malvern Instruments Ltd., Worcestershire, UK). Measurement of 
zeta potential was performed under similar conditions. DTS1070 disposable cuvettes were used 
(Malvern Instruments Ltd., Worcestershire, UK). The measurement data were evaluated using 
software provided by the manufacturer, and statistical data and graphs were created and evaluated 
with Origin 9.0 (OriginLab) and Microsoft Excel 2013 software. DLS measurements were performed 
weekly for a period of 6 weeks to determine colloidal stability. Samples were stored at 2–8 °C. 
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2.5. Atomic Force Microscopy (AFM) 
After a 10 min incubation time, mica surface was dried in N2 stream. AFM images were collected 
in noncontact mode with a Cypher S instrument (Asylum Research, Santa Barbara, CA, USA) at 1 Hz 
line-scanning rate in air, using a silicon cantilever (OMCL AC-160TS, Olympus, Japan) oscillated at 
its resonance frequency (300–320 MHz). Temperature during the measurements was 25 ± 1 °C. AFM 
amplitude-contrast images are shown in this paper. The filter used on the images enhances the details 
of the height contrast images (violet, orange, yellow). AFM images were analyzed by using the built-
in algorithms of the AFM driver software (Igor Pro, Wave Metrics Inc., Lake Oswego, OR). Particle 
statistics was done by analyzing a 4 µm × 4 µm height-contrast image with (n = 95) particles. 
Maximum height values were taken as the height of particles, and rectangularity was calculated as the 
ratio of the particle area to the area of a nonrotated inscribing rectangle. The closer a particle is to a 
rectangle, the closer this value is to unity. Detailed data is available in Supplemental Information Figure 
S5. 
2.6. Scanning Electron Microscopy (SEM) 
The nanoparticle suspension was diluted with distilled water (1:2) and applied to a metallic 
sample plate, which was covered with a double-sided carbon tape. The sample was dried under 
vacuum, metallized with gold and investigated with a field emission EM, JEOL JSM 6380LA SEM 
(Jeol Ltd., Japan), at 15 kV and a working distance of 15 mm. The morphology of the nanoparticles 
was observed. 
2.7. Transmission Electron Microscopy (TEM) 
Morphological investigations of the NPs were carried out on a JEOL JEM 1200EX (Jeol Ltd., 
Japan) transmission electron microscope. The diluted sample was dropped and dried on a carbon-
coated copper grid. The length (along multiple axles) and the area of the particles were determined 
by manually measuring the diameter (n = 304) and circumference (n = 176) of the nanoparticles, using 
ImageJ software. 
2.8. Animals 
In vivo fluorescent imaging tests of MB-PBNP nanosystems were carried out in C57BL/6 male 
mice (Janvier, France). Animals had ad libitum access to food and water and were housed under 
temperature-, humidity-, and light-controlled conditions. All procedures were conducted in 
accordance with the ARRIVE guidelines and the guidelines set by the European Communities 
Council Directive (86/609 EEC) and approved by the Animal Care and Use Committee of Semmelweis 
University (protocol number: XIV-I-001/29-7/2012). Mice were 10–12 weeks old with an average body 
weight of 28 ± 5 g. During imaging, animals were kept under anesthesia using a mixture of 2.5% 
isoflurane gas and medical oxygen. Their body temperature was maintained at 37 °C throughout 
imaging. For the most humane termination of the animals, intravenous Euthasol 
(pentobarbital/phenytoin) injection was used. 
2.9. In Vivo Fluorescent Imaging 
The fluorescent labelled PBNPs were imaged using a two-dimensional epifluorescent optical 
imaging instrument. (FOBITM, Fluorescent Organism Bioimaging Instrument; Neoscience Co., Ltd., 
Jangan-gu Suwon-si Gyeonggi-do, South Korea). Mice were anesthetized with isoflurane (5% for 
induction and 1.5–2% to maintain the appropriate level of anesthesia; Baxter, AErrane). Precisely, 200 
µL of MB-labelled PBNP solution containing 224 µg of Fe(III) in a 2 mg/mL concentration PBNP 
solution was administered intravenously into the tail vein. The images were collected (after shaving 
to remove hair) at 4 different time points (pre- and postinjection, 3 h postinjection, and ex vivo post 
the 3 h in vivo time) with excitation of 630–680 nm corresponding to the excitation maximum of the 
dye (ex: 664 nm; em: 687 nm). The emission spectrum of the dye was in the pass band of the used 
emission filter. Image acquisition parameters were the following: exposure time: 1000 msec and gain: 
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1. The images were evaluated with VivoQuant software (Invicro, 27 Drydock Avenue, Boston, MA, 
USA). 
3. Results 
3.1. Preformulation of PEGylated PBNPs 
Multiple approaches were made to determine the optimal PEG coating concentration. For that, 
different volume-percent compositions were formed and characterized. During the preformulation, 
DLS measurements were performed and combined with the macroscopic analysis of the samples 
(aggregation, visual evaluation, homogeneity, and homogenizability) (Table S2). 
We found that the optimal PEG concentration for the different types of PEG solutions is slightly 
different if the particle size and the PDI are the form factors for choice. For further inspections, PBNP-
MB samples containing 5 mg (10 µL) PEG 3000 (PNBP-MB@PEG3000_10µL), 10 mg (100 µL) PEG 
6000 (PNBP-MB@PEG6000_100µL), and 12.5 mg (100 µL) PEG 8000 (PNBP-MB@PEG8000_100µL) 
were chosen after DLS measurements and macroscopic inspections. The other samples showed either 
aggregation during the measurements or sedimented despite the optimal hydrodynamic diameter 
and low PDI value. The synthesized methylene-blue-labelled PEGylated PBNP-s (PBNP-MB@PEG) 
were stored at 2–8 °C. 
3.2. In Vitro Measurements 
3.2.1. DLS and Zeta Potential of Fluorescently Labelled PBNPs 
MB labelled, PEGylated PBNPs were measured first to determine the optimal size. These 
measurements were part of a preformulation study, which included mainly macroscopic inspections 
along with DLS and zeta potential measurements (Supplemental Information, Table S2). 
3.2.2. Atomic Force Microscopy (AFM) 
AFM images are shown in Figure 1. PBNPs appeared as objects with a flat rectangular surface 
protruding from a rounded halo (Figure 1a). The rectangular surface represents the real geometry of 
the particles (Figure 1c) while their halo is the consequence of tip convolution, i.e., the effect of 
imaging a rectangular prism by a tetrahedral AFM tip. Rectangularity of the particles (together with 
their halo) was found to be 0.7701 ± 0.1041 (mean ± SD), indicating that PBNPs indeed represent 
rectangular topography. The height of the particles showed monomodal distribution with a mean ± 
SD of 17.790 ± 8.922 nm (Figure 1). 
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Figure 1. (a) Height-contrast AFM image of PBNPs on the mica surface (scale bar = 4 µm × 4 µm). (b) 
Modified PBNPs on the mica surface; height-contrast AFM image (scale bar = 200 nm). (c) A modified 
PBNP nanoparticle (scale bar = 50 nm). (d) The cross-section graph of (c) PBNP nanoparticle (abscissa 
= 0–200 nm; ordinate = 0–25 nm). AFM: atomic force microscopy; PBNPs: Prussian blue nanoparticles. 
3.2.3. Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy 
Due to the sample preparation process, SEM images show an aggregated nanosystem where the 
particles appear as rectangular objects. Single particles were hard to distinguish from one another, 
however, their size did not exceed the 100 nm threshold (Figure 2a). 
The nonhydrated shape and size of the NPs were also analyzed with TEM (Figure 2b,c). The 
nanosystem was slightly aggregated (Figure 2c), however, single particles could be observed. The 
shape of the nanoparticles on TEM and AFM images was similar. PBNPs appeared as flat rectangular, 
dense objects in this case as well. The average length of the particles was 28.080 ± 6.690 (mean ± SD; 
n = 304) (Figure 2d), along with an average surface area of 582.20 ± 269.750 nm2 (mean ± SD; n = 176 
particles) (Figure 2e). 
 
Figure 2. (a) The SEM micrograph of modified PBNPs (magnification: 30,000x, scale bar = 0.5 µm); the 
PBNPs are barely visible between the pores of the double-sided carbon tape (section of (a); 
Nanomaterials 2020, 10, 1732 7 of 15 
 
magnification: 30,000x). (b–c) The TEM micrograph of modified PBNPs (magnification = 250,000x; 
scale bar = 100 nm). (d) The mean length of PBNPs, determined by TEM images. (e) The average area 
of the modified PBNPs according to TEM images. SEM: scanning electron microscopy; PBNPs: 
Prussian blue nanoparticles; TEM transmission electron microscopy. 
3.2.4. Measuring In Vitro Fluorescence 
After the two main approaches of fluorescent labelling, PBNP-MB@PEGs were tested in vitro, to 
study whether the emitted signal is adequate for in vivo imaging. For that purpose, 20-fold diluted 
samples were produced and measured, along with the stock PBNP-MB@PEG solutions. 
The samples prepared according to method a showed lower intensity on the emitted light, on 
the other hand, method b provided a significantly better signal in emission, which made the sample 
a better choice for in vivo use (Figure 3a,b). 
 
Figure 3. (a) PBNP-MB@PEG6000_100µL (stock solution 5x and 20x dilution left to right). (b) 
Fluorescent signal of PBNP-MB@PEG6000_100µL dilutions in FOBI. PBNP-MB@PEG6000_100µL: 
Methylene blue-labelled (100 µL Methylene blue) PEG 6000 stabilized Prussian blue nanoparticles; 
FOBI: Fluorescent Organism Bioimaging Instrument. 
3.2.5. Stability Measurements of PBNP-MB@PEG Nanoparticles 
The mean zeta potential of the measured samples (PBNP, PBNP-MB@PEG3000, PBNP-
MB@PEG6000, and PBNP-MB@PEG8000) was not bigger than −20 mV, moreover, all the samples had 
a net negative charge of −25 mV or greater. 
The mean hydrodynamic diameter of the particles was measured as a part of a 4-week stability 
test. However, non-modified PBNPs size showed a slight change in the diameter, i.e., after the third 
week, all PEGylated particles started to aggregate. PBNP-MB@PEG6000 nanoparticles were the most 
stable, along with the lowest PDI and diameter. As the size (hydrodynamic diameter) of the other 
two particles (PBNP-MB@PEG3000 and PBNP-MB@PEG8000) doubled after 3 weeks, the PBNP-
MB@PEG6000 particles kept a solid size of 24.82 ± 5.83 nm (number-based particle size distribution). 
According to these results, PBNP-MB@PEG6000 particles remained stable for the longest time, thus 
made them the best candidate for further inspections (Supplemental Information; Table S3 and Figure 
S6) 
3.3. In Vivo and Ex Vivo Measurements 
Due to the strong visible fluorescent signal of PBNP-MB@PEG6000s, 200 µL of the suspension 
of nanoparticles was injected into the lateral tail vein of C57BL/6 male mice Figure 4A,B. The 
semiquantitative distribution of the labelled PBNPs was determined based on their normalized mean 
fluorescent intensity (Figure S6). On the ex vivo images Figure 4B, taken 3 h after the first injection, 
PBNP-MB@PEG6000 accumulation can be observed in the gastrointestinal tract, kidneys, spleen, 
liver, and heart. 
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Figure 4. (A) (a, b) C57BL/6 mice before intravenous treatment from anterior and posterior planes. (c, 
d) C57BL/6 mice pre-PBNP treatment (anterior and posterior planes). (a) anterior, preinjection; (b) 
posterior, preinjection; (c) anterior, postinjection; and (d) posterior, postinjection. Color scale equals 
mean fluorescent intensity (MFI) in arbitrary units (A.U.) Figure 4 (B) ex vivo images, 3 h 
postinjection. 
4. Discussion 
It has long been known that Prussian blue (PB) is capable of chelating toxic metals, e.g., cesium 
(Cs) and thallium (Tl), thus facilitating their clearance from the body. This property is the main reason 
PB is featured on the World Health Organization (WHO) Model List of Essential Medicines, as the 
specific category “Antidotes and other substances used in poisoning” PB has been approved for 
medical use in the United States (US) and in Europe for the abovementioned indication since 2003 
[10,19]. Previous studies also described Prussian blue nanoparticles (PBNPs) as potential 
photothermal therapeutic agents [16], a promising candidate for different types of imaging [20], e.g., 
magnetic resonance-imaging (MRI) (as a T1 and T2 contrast agent) [12,21], optical imaging, and 
computed tomography [22]. The most widely used imaging modalities for follow-up studies are MRI 
and optical imaging (OI). MRI, based on the different relaxivities modulated by contrast agents (CA), 
is able to emphasize the structural (anatomical) differences between different types of tissues. MRI 
methods are noninvasive and can be easily translated from preclinical research to clinical 
applications, allowing the acquisition of spatial as well as temporal information. However, MRI 
suffers from less than optimum sensitivity of detection of injected CAs [23]. 
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Of the mentioned modalities, OI is, however, the least complicated and most versatile method in 
current preclinical imaging applications. OI is free from harmful effects of ionizing radiation—in fact, 
it replaces it with nonionizing radiation, which includes visible, ultraviolet, and infrared light [24]. 
Several approaches were made to synthesize multimodal nanoparticles, which were capable of 
optical imaging along with other imaging techniques or had notable therapeutic relevance. Dumont 
et al. described PBNP analogue Mn (II) containing fluorescent-labelled nanoparticles with pediatric 
brain tumor (PBT) specific antigens. These nanoparticles generated MRI contrast (in both T1 and T2) 
and showed specific uptake in PBTs due to their surface modifications. These modifications granted 
them biocompatibility and provided fluorescent signal in vivo [25]. 
Tu et al. has also described multimodal magnetic-resonance and optical-imaging contrast agent, 
which were sensitive to NADH. In the presence of NADH, the MRI signal enhanced, whereas the 
green fluorescence disappeared [26]. The contrast agent itself had a notable MR signal enhancement 
in vivo, the only drawback of its clinical application was the lack of specificity on a cellular level. 
Furthermore, the absorption peak of the molecule was found in the region of autofluorescence, which 
made it a less promising candidate for further use. 
To overcome the weakness in OI, Shcherbo et al., in his work, has discussed a protein known as 
mKate/Katushka (monomer/polymer), which could be excited at 588 nm and emits at 635 nm. At the 
far-red emission wavelengths, neither the absorbance of hemoglobin and melanin at 620 nm nor the 
absorbance of water at 1100 nm is significant, thereby providing greater penetration depth for detection 
in vivo [27]. Due to the lack of selectivity in fluorescent signal, this technique could not succeed in 
preclinical drug research, notwithstanding its novelty in whole-body imaging and gene manipulation. 
Despite other important results, Prussian blue nanoparticles were not yet been described as both 
fluorescent and PEGylated nanoscale platform for in vivo imaging. In our work, the fluorescence was 
provided with an adsorbed dye, namely, methylene blue (MB), which is a highly water-soluble 
fluorescent dye. MB is widely used in different fields of medicine: as the medication and treatment 
of methemoglobinemia and cyanide poisoning; as a part of combination of drugs in infection control, 
which covers the urinary tract; and as a strain or dye in different types of endoscopy [28–31]. 
In addition, the excitation of methylene blue is in the NIR region (above 630 nm). MB is also the 
most inexpensive of the commercially available NIR fluorescent dyes and has been widely used for 
bioanalysis [32]. Prussian blue nanoparticles were previously described as biosensors, based on their 
redox properties. Their peroxidase-like activity was in focus of the studies of Zhang et al. and 
Vázquez-González et al. Their studies suggest that the interaction of cells with PBPNs could enhance 
the effects of oxidative damage to cells, especially to the cells of the liver, which was observed in the 
work of Chen et al. [33–35]. To overcome the oxidative effects of PBNP administration, either 
reductive substance should be administered with the PBNPs or reductase-like activity should be 
attached to the surface of the PBNPs. Such reductive substances would prevent the effects of the 
PBNPs. MB is a strong antioxidant, which would prevent cellular oxidation damage as Zhang et al. 
describes, by preventing mitochondrial oxygen free radical formation and enhancing oxygen 
consumption [36]. Previous studies described MB as an encapsulated dye in different kinds of 
particles for fluorescent imaging [37,38]. In addition, Szigeti et al. and Chen et al. suggested that 
mesoporous PBNPs could act as “chemical sponges,” absorbing metal ions and drugs, depending on 
the pH conditions and properties of the PBNPs [13,39] Our results suggest similar mechanisms for 
labelling. The two applied methods were mainly different: method a suggested a connection based 
on surface charges and secondary bonds, where PEG had an additional function as sealant, 
preventing MB leakage. In contrast, method b showed less fluorescence, which suggest less adsorbed 
dye and therefore, poor labelling efficacy. The surface of PBNPs was “sealed” before MB could 
connect to the particles, which resulted in increased dye-washout during dialysis. 
Surface charge measurements have been concluded—they suggest a small decrease in the zeta 
potential after MB labelling (mean value before labelling <−30 mV; mean value after the labelling <−25 
mV). In addition, additional surface charge measurements were concluded, on older samples. Their 
zeta potential did not exceed −20 mV. Therefore, it is possible that the decreased surface charge is the 
result of the ionic interactions between the dye and the citrate surface. Nevertheless, it must not be 
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forgotten, that the pH of the used buffer (Phosphate buffer saline pH 6.8) could also result a decreased 
zeta potential in the MB-labelled PBNP sample. Previous studies described citric acid-, PVP-, and 
PEG-coated PBNPs. These capping agents are biocompatible and act mainly as steric stabilizers, 
which enhance the colloidal stability of the particles and affect the size and shape of the nanoparticles 
[40–42]. 
Chelating properties of citric acid were previously reported; citrate forms complexes with 
metallic cations although, at physiological conditions, these complexes have no effect on the colloidal 
stability of the particles [43,44]. Both citric acid and PEG offer PBNPs biocompatibility, moreover, 
citrate as a capping agent could function as an anchor for different molecules due to its terminal 
carboxylic function. PEG and citric acid were reported to form aggregates, connected with π-bonds, 
depending on the concentration and the proportion of citric acid to PEG [17,18]. 
The reported PEGylated MB-labelled PBNPs remained stable for about 3 weeks, while the 
previously reported, citrate-coated PBNPs did not aggregate in a biologically relevant manner after 
4 weeks [9,18]. This lets us conclude that the increased complexity on the nanoparticle surface leads 
to a shorter stability and usability. Based on the studies of Namazi et al. and Naeini et al., over time, 
citric acid and PEG are forming a self-aggregating system in our samples [7,15]. These dendrimers 
would offer a protective layer for PBNPs while encapsulating them along with the fluorescent dye 
MB. Our results suggest that further improvement would be necessary to synthesize a more stable 
PBPN platform for multimodal use as, e.g., MR-CA, radiotracer or therapeutic functions. 
FTIR spectroscopy reveals the lengths of the bonds, the molecular mass changes, and the band-
order of molecules. Hypsochromic shifts (shifts to lower wavenumbers) suggest that the mass of the 
corresponding molecule has been increased; the frequency of vibration is inversely proportional to 
mass of vibrating molecule. In addition, the absorption bands near 3415 and 1610 cm−1 refer to the O–
H stretching mode and H–O–H bending mode, respectively, indicating the presence of interstitial 
water in the samples (Figure S8a–d) [45–47]. 
In medical imaging, the safety and discomfort of patients are important; therefore, a significantly 
faster and safer method used for lengthy and repeated procedures could make a huge impact on both 
diagnostics and monitoring. Optical methods are peculiarly useful for visualizing soft tissues, which 
can be easily differentiated from each other based on their light-absorbing and -scattering capabilities. 
The dual modalities allow better chances for inspection, based on different kinds of imaging modalities, 
e.g., MRI and OI. Finally, if an acute intervention is required, the need of repeated CA administration 
could be preventable, if the half-life (and clearance) of the nanoteragnostic agent is adequate. 
The total workings of the immune system play a significant role in the distribution, metabolism, 
and elimination of nanoparticles. As Diao et at. and Hong et al. used C57BL/6 mice of IR imaging, we 
also decided to test our nanosystem in C57BL/6 mice that have an intact immune system as opposed 
to immunocompromised nude mice [48,49]. This might have made our imaging signals more 
scattered, but increased the validity of the model towards, eventually, clinical translational studies. 
The elimination and excretion of nanoparticles is, however, poorly investigated. Due to its 
mainly oral administration, only a few studies have been published data regarding I.V. PB 
administration. As far as we know, ultrasmall PBNPs tend to be excreted via glomerular pathways, 
while after oral administration, PBPNs are excreted via fecal and urine routes [13,50,51]. The few 
available reports dealing with biodistribution and elimination of PBNPs after intravenous injection 
are not conclusive. It would seem, though, that in those studies, kidney excretion was not relevant 
despite smaller PBNP deposits in the mesangium and the peritubular vessels of [13,15]. Our findings 
with the new coating and dye-adsorbed-modified PBNPs suggest that both kidney and biliary 
elimination routes play a major role in the excretion of this nanoparticle system. Shortly after iv. 
administration, the particles could be found in the urinary tract, showing an enhanced fluorescent 
signal 3 h after the admission. This, along with our former data obtained with irreversibly 201Tl-
isotope-labelled PBNPs passing through the kidney to the urinary excretion route, suggests a portion- 
of kidney excretion via fenestrae of the kidney endothelium and podocytes, especially in our 
measured hydrodynamic size range below 40 nm [13]. 
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In order to account for eventual dissociation of the MB dye from PBNP surfaces, we compare 
the known elimination routes and dynamics of MB dye solution to our MB-labelled PBNPs. Peter et 
al. reported that while MB alone accumulates in the brain and bile, mainly urinary excretion is 
significant 1 h after IV administration. The maximal concentration during urinary excretion was 
reached 2–4 h after administration [52]. In this context, our results suggest that MB stayed bound to 
PBNPs as both renal clearances are prolonged while the PEG shell alone did not significantly increase 
the renal excretion speed. The fluorescent intensity in the heart, liver, and spleen suggest a prolonged 
circulation time. Significant uptake can be observed in the lungs (501% ± 85%; 2 h post injection 156% 
± 60%) and spleen (163% ± 18%), while a slight increase in fluorescent intensity in the intestines (107% 
± 5%), along with the urinary excretion (272% ± 32%; 3 h post injection 177% ± 20%) (percent values 
based on normalized fluorescent intensities preinjection ± SD). These results suggest that the MB and 
PBNPs were connected, and their clearance followed the both characteristic pathways for MB and 
PBNP; furthermore, the PEG shell alone did not promote the renal excretion significantly. The 
fluorescent intensity in the heart, liver, and spleen suggest a prolonged circulation time (Figure S6). 
The ex vivo images confirm that the application of PEG led to an increased biological half-life 
and slowed excretion rate, both biliary and urinary, compared to previous studies [53–55]. Even if 
other studies emphasize the connection between filtration and negative surface charge and larger 
particle size, PEGs are known as rather neutrally charged stabilizers. According to Liu et al. and 
Souris et al., complete clearance of PEG-modified nanoparticles last for 2 months, and thus, show a 
tendency of hepatic and renal accumulation causing local inflammation and necrotizing tissue 
[56,57]. 
Chen et al. investigated the acute and subchronic toxicological properties of Prussian blue 
nanoparticles after exposure of mice. PBNPs accumulated mainly in the spleen and liver. They found 
that, however, PBNPs induced acute damage in the liver (based on the liver functions), the long-term 
effects of PBNP-treatment cannot be called negative. All monitored parameters returned to normal 
levels, 60 days after the first IV PBNP administration [35]. Our results also confirm the claims of Chen 
et al.; in the ex vivo images (Figure 4), PBNPs were present in the spleen and the liver; biliary 
functions resulted in PBNP presence in the gastrointestinal tract. 
The nontoxic properties of PBNPs were also confirmed by the study of Liang et al. Furthermore, 
they evince that no significant or fatal injury can be attributed to PBNP treatment, neither on 
histological nor on macroscopic matter. The vital organs were unharmed, no injuries were present on 
cellular levels 2 weeks and 4 weeks after the treatment [58]. 
Although fluorescent imaging capabilities of PBNPs were demonstrated in this work, further 
optimization and development of the platform is essential before any clinical implementation. Based 
on our work, the scale-up of PBNP-based CA is yet to be done while long-term studies for usability 
and effects in vivo are needed before human studies, too. 
Our results suggest the use of PBNPs as a platform for the development of new-generation 
multimodal CAs, for OI and MRI imaging as well as therapeutic purposes. The biocompatible shell 
of the NPs is easy to modify due to the carboxylic groups, which would allow the cell or tissue 
targeted delivery. The targetable magnetic properties of the NPs would allow their theragnostic use, 
too, with proper selection of effector payload such as antibodies; thus, allowing a new type of topical 
infection-control method against bacterial and viral infections. 
Such a NP system would act as CA in vivo as well as as a therapeutic agent for photothermal, 
isotope-based, biological or stem cell therapies, opening new aspects in the future of medicine. 
5. Conclusions 
In this work, we demonstrated a synthesis and modification methodology to biocompatible 
stealth fluorescent PBNPs. We created a novel nanoparticulate contrast material for the classical 
methodology of fluorescent measurements, e.g., using FOBI. Our results suggest that the stealth-
liposome-like platform is suitable for fluorescent imaging. 
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We investigated the PB nanoobjects in vivo after intravenous admission and examined the 
elimination routes of these particles. We described the hepatobiliary and renal uptake and excretion 
to be both important in our system with in vivo intravenous application. 
With both PEGylation and fluorescent labelling PB nanoparticles can be conferred with 
advanced technological properties to offer a finely tuned platform for clinical application after further 
development. We aim towards clinical translation hence the application of MB and NIR wavelength 
usage too. As fluorescent detection and imaging data in a suboptimal in vivo system are more 
convincing to extend towards human clinical trials, the use of standard and more clinically valid 
Black mice might have been a better choice for validity and detection studies than transparent but 
less clinically translatable nude mouse study. 
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